Key Takeaways
- Novo Nordisk received an FDA warning letter dated March 5 addressing failures in reporting adverse events connected to semaglutide, found in Ozempic and Wegovy.
- The letter referenced three fatalities, including a suicide case that Novo allegedly failed to investigate and report according to regulations.
- The company has a two-week deadline to outline corrective measures to the FDA.
- Novo maintains that the warning will have no effect on manufacturing operations or financial projections.
- Shares of NVO have declined 27% year to date, currently trading near $38.32.
The Danish pharmaceutical giant continues to face mounting challenges in 2026.
On March 5, federal regulators sent a warning letter to Novo Nordisk, highlighting “serious violations” concerning the company’s adverse event reporting practices for semaglutide, the compound behind Ozempic and Wegovy.
Regulators uncovered these violations while conducting an inspection at a Novo facility in New Jersey during the previous year.
The letter specifically highlighted three fatalities, among them a suicide case. According to the FDA, Novo failed both to investigate the suicide and to submit required reports within the designated timeframe.
The agency emphasized that it has made no determination regarding whether the medications directly caused these deaths. The focus centers entirely on procedural compliance with reporting requirements.
“FDA relies on the complete, accurate, and timely submission of ADEs to monitor a product’s safety profile,” regulators stated, using the acronym for adverse drug events.
Novo Nordisk must inform the FDA within two weeks about corrective actions planned to address these violations.
In a public statement, the pharmaceutical company indicated it has been working “diligently” to resolve the FDA’s concerns. The company confirmed submitting an initial response along with seven subsequent updates.
The company stated that the cases mentioned in the letter “have been evaluated” and are now “processed and reported appropriately.” Novo did not dispute the original reporting failures.
Regulatory Challenges Mount for Drugmaker
This warning represents the latest in a series of regulatory setbacks for Novo. December brought a separate warning letter directed at the company’s Bloomington, Indiana manufacturing site regarding Good Manufacturing Practice violations.
February saw the FDA send two additional letters challenging marketing materials for Ozempic and Wegovy, citing “false or misleading claims” about effectiveness and safety information. A February 26 letter specifically challenged Novo for positioning Ozempic as better than alternative treatments.
In its press release addressing these issues, Novo stated: “We work in a highly regulated space.”
Company officials maintain that this most recent warning will have no impact on manufacturing capabilities or the financial outlook previously communicated to shareholders.
Shares Decline 27% in 2026
Investors have punished NVO throughout the current year. Trading around $38.32, the stock has surrendered 27% of its value year to date, significantly below previous peak levels.
Multiple factors have contributed to the decline. Regulatory scrutiny combined with intensifying competition from Eli Lilly’s Mounjaro, a competing GLP-1 medication, have dampened investor confidence.
Political factors have compounded market pressures. Health Secretary RFK Jr. has openly criticized Ozempic’s pricing, while last year he blocked a Biden administration initiative that would have extended Medicare coverage for GLP-1 medications to approximately 7 million beneficiaries.
As of Tuesday afternoon, shares were priced at $38.32.
